tabelecleucel
Cell therapyexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Dec 29, 2017 (NCT03394365)
Timeline
Indications
Studied for
- Epstein-Barr Virus Infections · Phase 2
- Hematopoietic Stem Cell Transplantation · Phase 3
- Herpesvirus 4, Human · Phase 2
- Leiomyosarcoma · Phase 2
- Lymphohistiocytosis, Hemophagocytic · Phase 2
- Lymphoproliferative Disorders · Phase 3
- Nasopharyngeal Carcinoma · Phase 1/Phase 2
- Nasopharyngeal Neoplasms · Phase 1/Phase 2
- Organ Transplantation · Phase 3
- Primary Immunodeficiency Diseases · Phase 2
- Sarcoma · Phase 2
Mechanism of action
- Unspecified targetOTHER
The T-cell receptor recognises an EBV peptide in complex with a specific HLA molecule on the surface of target cells to exert cytotoxic activity
EBNA1 other
- Human herpesvirus 4Immunity, passive
Human herpesvirus 4 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3990008 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04554914 | Phase 2 | Nov 30, 2020 | Atara Biotherapeutics |
| NCT03769467 | Phase 1/Phase 2 (Phase 2) | Nov 28, 2018 | Atara Biotherapeutics, Merck |
| NCT03392142 | Phase 3 | Dec 29, 2017 | Atara Biotherapeutics |
| NCT03394365 | Phase 3 | Dec 29, 2017 | Atara Biotherapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Atara Biotherapeutics | For profit | 4 | 4 | 2 | 2017 |
| Merck | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1